Analyst Research Report Snapshot

Title:

ACTIVE BIOTECH - HIDDEN ASSETS

Price:

$10.00

Provider:

Edison Investment Research

Date:

21 Feb 2012

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ACTI.ST

Available for Immediate Download
Summary:

Active Biotech may at last be emerging from the cloud caused by last year’s near miss in the BRAVO Phase III study of laquinimod and low visibility of its partner Teva’s future study plans for the MS drug. However, investor attention may shift from this product this year as the read-out of the Anyara Phase II/III study approaches. Furthermore, tasquinimod’s move into Phase III studies last year in the currently “hot” CRPC indication has also seemingly been largely overlooked.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.